Patrick Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared a post on X:
“Great announcement today by HHS and NCI to support cancer vaccine trials. We have spent the past decade collaborating with 2 amazing thought leaders at the National Cancer Institute (NCI) in the field of cancer vaccine, Dr James Gulley and Dr Jeffrey Schlom.
Together we have completed Phase 1 and 2 trials across multiple tumor types showing how our Adeno vaccine plus Anktiva generates tumor specific T cells.
The randomized trial to Prevent cancer in subjects with Lynch Syndrome which affects over a million Americans (1 in 278) is fully enrolled and the early data so far shows that Anktiva and the Adeno vaccine increases NK and T cells in these subjects, even in subjects aged 65.”
Other articles about Patrick Soon-Shiong on OncoDaily,